Evidence map›Paper›PMID 41424934›Full record

ArticleBlood neoplasia2025

Correlates of organ damage in patients with advanced systemic mastocytosis enrolled in clinical trials of avapritinib.

Emily C Liang, Cecelia Perkins, Rong Lu, Hongliang Shi, Saša Dimitrijević, Justin Abuel, Cheryl Langford, Parveen Abidi, Lenn Fechter, William Shomali and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood neoplasia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Emily C LiangDivision of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, WA.
Cecelia PerkinsDivision of Hematology, Stanford University School of Medicine/Stanford Cancer Institute, Stanford, CA.
Rong LuQuantitative Sciences Unit, Department of Medicine, Stanford University School of Medicine, Stanford, CA.
Hongliang ShiBlueprint Medicines Corporation, Cambridge, MA.
Saša DimitrijevićBlueprint Medicines Corporation, Zug, Switzerland.
Justin AbuelDivision of Hematology, Stanford University School of Medicine/Stanford Cancer Institute, Stanford, CA.
Cheryl LangfordDivision of Hematology, Stanford University School of Medicine/Stanford Cancer Institute, Stanford, CA.
Parveen AbidiDivision of Hematology, Stanford University School of Medicine/Stanford Cancer Institute, Stanford, CA.
Lenn FechterDivision of Hematology, Stanford University School of Medicine/Stanford Cancer Institute, Stanford, CA.
William ShomaliDivision of Hematology, Stanford University School of Medicine/Stanford Cancer Institute, Stanford, CA.
Jason GotlibDivision of Hematology, Stanford University School of Medicine/Stanford Cancer Institute, Stanford, CA.

Funding

RESEARCH TRAINING IN HEMATOLOGYT32HL007093 · NHLBI · UNIVERSITY OF WASHINGTON · PI Janis L Abkowitz · 1985 to 2026
$13.9M
NHLBI NIH HHS T32 HL007093
6 · The paper itself

Abstract

Organ damage in patients with advanced systemic mastocytosis (AdvSM) at the time of enrollment in clinical trials of KIT inhibitors has not been well characterized. We describe the spectrum and clinicopathologic correlates of organ damage as defined by World Health Organization (WHO) and modified International Working Group-Myeloproliferative Neoplasms Research and Treatment and European Competence Network on Mastocytosis (mIWG) criteria among patients with AdvSM enrolled in the phase 1 and 2 trials of the

Identifiers

PMID41424934
PMCPMC12711656

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.